Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- NeuroBo Pharmaceuticals Inc.
- ID
- NCT04603924
- Phase
- Phase 2/3 COVID-19 Research Study
- Study Type
- Interventional
- Participants
- Expecting 436 study participants
- Last Updated